Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Ovarian Neoplasms

Free Subscription 15.02.2021 1 Am J Obstet Gynecol 1 Br J Cancer 6 Cancer Res 1 Clin Cancer Res 5 Gynecol Oncol 1 Hum Pathol 3 J Clin Oncol 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Obstet Gynecol

1. HARRISON RF, Fu S, Sun CC, Zhao H, et al
   Patient cost-sharing during poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer.
   Am J Obstet Gynecol. 2021 Feb 4. pii: S0002-9378(21)00086.
   PubMed         Abstract available
   
   

   
   Br J Cancer

2. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
   Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
   Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
   PubMed         Abstract available
   
   

   
   Cancer Res

3. GEISTLINGER L, Oh S, Ramos M, Schiffer L, et al
   Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma.
   Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-20-0521.
   PubMed         Abstract available
   
   
4. SHEN YA, Hong J, Asaka R, Asaka S, et al
   Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
   Cancer Res. 2020;80:4514-4526.
   PubMed         Abstract available
   
   
5. AZAR WJ, Christie EL, Mitchell C, Liu DS, et al
   Non-canonical IL-6 signaling-mediated activation of YAP regulates cell migration and invasion in ovarian clear cell cancer.
   Cancer Res. 2020 Sep 11. pii: 0008-5472.CAN-19-3044.
   PubMed         Abstract available
   
   
6. DRERUP JM, Deng Y, Pandeswara SL, Padron AS, et al
   CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
   Cancer Res. 2020;80:5063-5075.
   PubMed         Abstract available
   
   
7. TAMURA N, Shaikh N, Muliaditan D, Soliman TN, et al
   Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.
   Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-0852.
   PubMed         Abstract available
   
   
8. BELUR NAGARAJ A, Knarr M, Sekhar S, Connor RS, et al
   The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.
   Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-2041.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. LI N, Bu H, Liu J, Zhu J, et al
   An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
   Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3546.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

10. DAI Y, Wang Z, Wang J
    Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
    PubMed         Abstract available
    
    
11. SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
    The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
    PubMed         Abstract available
    
    
12. BAE-JUMP V
    Unraveling the mystery of clear cell endometrial cancer.
    Gynecol Oncol. 2020;158:1-2.
    PubMed        
    
    
13. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    PubMed         Abstract available
    
    
14. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    PubMed         Abstract available
    
    

    
    Hum Pathol

15. TESSIER-CLOUTIER B, Cochrane DR, Karnezis AN, Colborne S, et al
    Proteomic Analysis of Transitional Cell Carcinoma-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma.
    Hum Pathol. 2020 Apr 29. pii: S0046-8177(20)30047.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

16. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    PubMed         Abstract available
    
    
17. PAULINO E, Melo AC
    SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
    J Clin Oncol. 2020;38:2697-2698.
    PubMed        
    
    
18. PENSON RT, Lowe ES
    Reply to E. Paulino et al.
    J Clin Oncol. 2020;38:2698.
    PubMed        
    
    

    
    Proc Natl Acad Sci U S A

19. IWAHASHI N, Ikezaki M, Nishikawa T, Namba N, et al
    Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
    Proc Natl Acad Sci U S A. 2020;117:33225-33234.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: